Humanitarian Organization Criticizes Eli Lilly, Novo Nordisk And Sanofi Of Having 'Double Standards' For High Insulin Price
Humanitarian Organization Criticizes Eli Lilly, Novo Nordisk And Sanofi Of Having 'Double Standards' For High Insulin Price
Ahead of World Diabetes Day, Doctors Without Borders/Médecins Sans Frontières (MSF) called for all insulin manufacturers to provide injection pen devices at $1 per pen.
在世界糖尿病日到来之前，无国界医生组织呼吁所有胰岛素制造商将注射笔设备的价格定为每支1美元。
The humanitarian organization emphasized that this would help ensure access to life-saving treatment for millions in low- and middle-income countries, where many struggle to afford diabetes care.
这家人道主义组织强调，这将帮助确保低收入和中等收入国家数百万人的生命救治，他们在糖尿病护理方面苦苦挣扎，难以负担。
MSF highlighted that Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), and Sanofi SA (NASDAQ:SNY), which dominate the global insulin market, have the power to set high prices that restrict access.
无国界医生指出，主导全球胰岛素市场的礼来（纽交所：LLY）、诺和诺德（纽交所：NVO）和赛诺菲（纳斯达克：SNY）有能力设定高价，从而限制获取。
Also Read: Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
另请参阅：施贵宝斐德表现抢眼，市值增长近25%，但诺和诺德和礼来遭遇市场挫折
According to MSF, data published in JAMA Network Open shows that insulin pens could be produced for as little as $0.94 per unit and remain profitable, yet current prices far exceed this figure.
根据无国界医生的数据，发表在《JAMA网络开放》上的数据显示，胰岛素笔每个单位的生产成本低至0.94美元，仍然可以盈利，但目前价格远远高于这一数字。
For instance, a pen costs $1.99 in South Africa, $5.77 in India, $14.00 in the Philippines, and $90.69 in the U.S.
例如，在南非，一支笔的价格为1.99美元，在印度为5.77美元，在菲律宾为14.00美元，而在美国为90.69美元。
Dr. Helen Bygrave, an advisor for MSF's Access Campaign, underscored the disparity by recalling the initial intentions of the scientists who discovered insulin. "Over 100 years ago, they sold the patent for just $1 to ensure global access. Now, only about half of those who need insulin can access it," she said.
无国界医生的获取运动顾问海伦·拜格博士强调了差异，回忆起发现胰岛素的科学家的初衷。"在100多年前，他们以仅1美元的价格出售专利，以确保全球获取。现在，只有大约一半需要胰岛素的人能够获取它，"她说。
She stated that the corporate control by Eli Lilly, Novo Nordisk, and Sanofi has led to a "double standard" that hinders equitable diabetes treatment.
她表示，礼来、诺和诺德和赛诺菲的公司控制导致了一个"双重标准"，阻碍了公平的糖尿病治疗。
In July, the FDA rejected Novo Nordisk's BLA filing for the once-weekly insulin icodec.
在七月，FDA拒绝了诺和诺德的每周一次胰岛素icodec的BLA申请。
Insulin pens, known for their dosing accuracy and user-friendly design, have been preferred by 82% of surveyed diabetes patients due to their convenience and less invasive administration compared to vials and syringes.
胰岛素笔因其剂量准确和易于使用的设计而受到82%受访糖尿病患者的青睐，因为与瓶和针筒相比，它们更便捷且侵入性更小。
Recently, Novo Nordisk decided to cease insulin pen production to prioritize its GLP-1 medications for diabetes and obesity, like Ozempic and Wegovy.
最近，诺和诺德决定停止胰岛素笔的生产，以优先考虑其用于糖尿病和肥胖症的GLP-1药物，如Ozempic和Wegovy。
This shift, motivated by profit margins in wealthier markets, could force many patients back to using syringes and vials.
这一转变是由于在富裕市场的利润空间，可能迫使许多患者重新使用针筒和瓶装胰岛素。
South Africa, which transitioned to insulin pens in its public sector in 2014, recently faced a shortage that led to rationing when Novo Nordisk paused the supply of human insulin pens to the government.
南非自2014年在其公共部门转向使用胰岛素笔后，最近面临短缺，导致在诺和诺德暂停向政府供应人胰岛素笔时实施配给。
- FDA Commissioner Califf Candid on Trump's Impact: 'We Just Don't Know What's Going to Happen'
- FDA局长卡利夫坦诚谈特朗普的影响：‘我们不知道会发生什么’
Photo by towfiqu barbhuiya via unsplash
照片由towfiqu barbhuiya通过unsplash拍摄
